Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The copenhagen general population study

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 9, 2016, Pages 965-974

  Vedel Krogh, Signe ^a,b   Nielsen, Sune F ^a,b   Lange, Peter ^a,c,d   Vestbo, Jørgen ^e   Nordestgaard, Børge G ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Epidemiology; Granulocytes; Lung disease; Prospective study

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; SHORT COURSE THERAPY; SPIROMETRY; SYSTEMIC THERAPY; BLOOD; DENMARK; EOSINOPHIL; LONGITUDINAL STUDY; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIROMETRY; YOUNG ADULT;

EID: 84988952068     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201509-1869OC     Document Type: Article

References (24)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2095-2128.
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157: 1418-1422.
3. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187: 347-365.
4. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1: 39-47.
5. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184: 662-671.
6. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2000;356: 1480-1485.
7. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: Predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27: 964-971.
8. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 2007;29: 906-913.
9. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE investigators. Eosinophilic inflammation in COPD: Prevalence and clinical characteristics. Eur Respir J 2014;44: 1697-1700.
10. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebocontrolled trial. Am J Respir Crit Care Med 2012;186: 48-55.
11. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3: 435-442.
12. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192: 523-525.
13. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Late-breaking abstract: Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The Copenhagen General Population Study [abstract OA2934]. Eur Respir J 2015;46(Suppl 59). DOI: 10.1183/13993003.congress-2015.OA2934
14. Bakke PS, Rönmark E, Eagan T, Pistelli F, Annesi-Maesano I, Maly M, Meren M, Vermeire Dagger P, Vestbo J, Viegi G, et al.; European Respiratory Society Task Force. Recommendations for epidemiological studies on COPD. Eur Respir J 2011;38: 1261-1277.
15. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013;309: 2353-2361.
16. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis. Eur Respir J 2014;44: 789-791.
17. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60: 193-198.
18. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158: 1511-1517.
19. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial. JAMA 2013;309: 2223-2231.
20. Price D, Rigazio A, Postma D, Papi A, Guy B, Augusti A, Anzueto A, Vogelmeier C, Ryan D, Freeman D, et al. Blood eosinophilia and the number of exacerbations in COPD patients [abstract]. Eur Respir J 2014;44(Suppl 58).
21. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J; International COPD Study Group. Multicentre randomised placebocontrolled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351: 773-780.
22. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet 1999;354: 456-460.
23. Hospers JJ, Schouten JP, Weiss ST, Rijcken B, Postma DS. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 1999;160: 1869-1874.
24. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014;2: 891-901.